在北欧某医疗系统将成人估算肾小球滤过率的CKD-EPI方程转换为EKFC肌酐方程
EKFC方程使eGFR中位数降低4.9 ml/min/1.73 m²,CKD G3-G5患病率由4.5%升至6.2%,并影响肾病转诊、SGLT2抑制剂资格及螺内酯禁忌等临床决策。
要点
- EKFC方程较CKD-EPI使eGFR中位数降低4.9 ml/min/1.73 m²,CKD G3-G5患病率从4.5%升至6.2%。
- 两方程均强预测KFRT、死亡和MACE;EKFC重分类至较低eGFR组者调整年龄后死亡和MACE风险相似,KFRT风险更低。
- 转换为EKFC后,低eGFR阈值相关临床决策变化:肾病转诊增加22%,SGLT2抑制剂资格增加39%,心衰螺内酯禁忌增加26%。
核心结论
- 在此北欧医疗系统采用EKFC方程会适度降低eGFR估计值,增加中重度CKD患病率并影响临床分类和决策;两方程均强预测结局,但EKFC重分类至较低eGFR类别者在各结局上关联不一致。
主要发现
- EKFC较CKD-EPI的eGFR中位数(IQR)低4.9(8.3至2.2)ml/min/1.73 m²。
- CKD G3-G5患病率从4.5%升至6.2%。
- 两方程均强预测KFRT、死亡和MACE。
- 重分类至较低eGFR类别者年龄更大;调整年龄后,其死亡和MACE风险与未重分类者相似,KFRT风险更低。
- 转换为EKFC后,低eGFR阈值相关决策变化:肾病转诊增加22%,SGLT2抑制剂资格增加39%,心衰螺内酯禁忌增加26%。
关键数值与推荐
- EKFC较CKD-EPI的eGFR中位数(IQR)低4.9(8.3至2.2)ml/min/1.73 m²。
- CKD G3-G5患病率从4.5%升至6.2%。
- 转换为EKFC后,肾病转诊增加22%,SGLT2抑制剂资格增加39%,心衰螺内酯禁忌增加26%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Kidney Function Consortium (EKFC) 2021 equation to estimate GFR performs as well or better than the CKD-EPI 2009 equation in predominantly White adult European populations, with less bias and greater accuracy against measured GFR. This study explores how changing from the CKD-EPI to the EKFC equation in a large European health system may affect disease distribution, prognosis, and clinical decisions. METHODS: We studied >1.7 million adults in Stockholm undergoing routine care during 2006-2021. We compared eGFR values and reclassification across KDIGO GFR categories when changing from the CKD-EPI to EKFC equation and examined associations of eGFR and reclassification with risk for kidney failure with replacement therapy (KFRT), mortality, and major adverse cardiovascular events (MACE) using Cox models. We also modeled the impact of eGFR equation change on clinical decisions such as nephrology referral or medication eligibility/contraindication. RESULTS: EKFC yielded modestly lower eGFR values than CKD-EPI by a median (IQR) of -4.9 (-8.3 to -2.2) ml/min/1.73 m². As a result, CKD G3-G5 prevalence rose from 4.5% to 6.2%. Both equations strongly predicted KFRT, mortality, and MACE. Participants reclassified to lower eGFR categories were older; after adjustment for age, participants had similar risks of mortality and MACE to those not reclassified and a lower risk of KFRT. Changing to the EKFC equation would impact clinical decisions at low eGFR thresholds, such as nephrology referrals (22% higher), eligibility for SGLT2 is (39% higher), or contraindication for spironolactone in heart failure (26% higher). CONCLUSIONS: Adopting the EKFC equation in this Northern European health system would modestly lower eGFR estimates, increasing the prevalence of moderate/severe CKD and affecting clinical classification and decisions. eGFR by both equations strongly predicted outcomes, but individuals reclassified to a lower eGFR category by EKFC did not have consistent associations across outcomes.
引用
- Russel WA, Fu EL, Creon A, et al. Changing from the CKD-EPI to the EKFC creatinine equation to estimate glomerular filtration rate in adults in a Northern European health system. Nephrol Dial Transplant. 2026. PMID: 40796100. doi:10.1093/ndt/gfaf148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。